Highlight
The prevalence of impaired awareness of hypoglycemia (IAH) in youth with type 1 diabetes decreased markedly from 33.1% in 2002 to 15.9% in 2024. Concurrently, the rate of severe hypoglycemia (SH) dropped 30-fold over the same period despite improvements in glycemic control. Continuous glucose monitoring (CGM) metrics revealed no significant differences in hypoglycemia exposure between youth with and without IAH in 2024. These findings underscore improved diabetes management and the persistent need for routine IAH screening.
Study Background
Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by insulin deficiency, necessitating lifelong insulin replacement therapy. Hypoglycemia, particularly severe hypoglycemia (SH) that impairs consciousness or requires assistance, remains a critical complication affecting the safety and quality of life of youth with T1D. Impaired awareness of hypoglycemia (IAH) — a diminished ability to perceive hypoglycemia symptoms — increases the risk of SH and adverse outcomes such as seizures, accidents, and even death.
Over the past two decades, advances in diabetes care, such as improved insulin regimens, patient education, and continuous glucose monitoring (CGM), have aimed to reduce hypoglycemia burden. However, population-level data assessing temporal changes in IAH prevalence and SH rates among youth have been sparse. This study addresses this gap by comparing cohorts over a 22-year span to evaluate trends in IAH and SH, providing evidence for the impact of evolving clinical practices on hypoglycemia risk.
Study Design
This population-based observational study analyzed youth aged 12 to 18 years with type 1 diabetes sampled in three distinct calendar years: 2002, 2015, and 2024. Impaired awareness of hypoglycemia was assessed using a Modified Clarke questionnaire, a validated tool that gauges symptomatic recognition of hypoglycemia. Severe hypoglycemia events in the recent period were recorded and compared between cohorts. Additionally, in the 2024 cohort, CGM-derived glucose metrics were analyzed to assess glycemic exposure patterns among participants with versus without IAH.
Key Findings
Prevalence of Impaired Awareness of Hypoglycemia: The study observed a significant reduction in IAH prevalence across cohorts: from 33.1% in 2002, to 21.4% in 2015, and finally 15.9% in 2024 (p < 0.001 for 2002 vs 2024; p = 0.051 for 2015 vs 2024). This indicates a substantial improvement in symptomatic hypoglycemia recognition over two decades in youth with T1D.
Severe Hypoglycemia Rates: The rate of SH in 2024 was 0.92 events per 100 patient-years, representing a 3.5-fold decrease compared to 2015 (95% CI 1.2 to 12.5) and a striking 30-fold reduction from 2002 levels (95% CI 12.7 to 98.9). These decreases occurred despite a significant reduction in mean HbA1c levels across the cohorts (p < 0.001), suggesting improved glycemic control alongside enhanced hypoglycemia safety.
Continuous Glucose Monitoring Metrics: CGM data from the 2024 cohort showed that hypoglycemia exposure, measured by time below range and other glucose variability parameters, did not differ significantly between youth with and without impaired awareness of hypoglycemia (p > 0.05). This may reflect advancements in technological management tools that mitigate hypoglycemia risk irrespective of subjective symptom awareness.
Expert Commentary
The observed decline in IAH and SH rates in youth with T1D over the past two decades is likely multifactorial. The advent and widespread adoption of CGM technology have revolutionized glucose monitoring by providing real-time trend information, alarms for hypoglycemia, and data fusion with insulin pump therapies enabling automated insulin delivery. Furthermore, structured education programs emphasizing hypoglycemia recognition and prevention, along with improved insulin analogs with more physiological profiles, have contributed to safer and more effective management.
Nevertheless, the persistence of IAH in approximately 16% of youth in 2024 highlights an ongoing challenge. IAH remains a known risk factor for SH and adverse outcomes. The lack of differences in CGM-derived hypoglycemia exposure between groups suggests that mechanisms beyond glucose metrics—such as adaptive autonomic responses and individual neurophysiological differences—may contribute to impaired awareness. Routine clinical screening using validated tools like the Clarke questionnaire remains essential, alongside personalized interventions targeting hypoglycemia unawareness, including frequent monitoring, education, and consideration of advanced technologies.
Limitations of this study include its observational design and potential variability in cohort characteristics or treatment access over time. However, its population-based approach and repeated cross-sectional assessments strengthen its external validity and clinically relevant insights.
Conclusion
This study demonstrates a significant and encouraging decline in the prevalence of impaired awareness of hypoglycemia and rates of severe hypoglycemia among youth with type 1 diabetes from 2002 to 2024. These improvements mirror advancements in diabetes technology, treatment strategies, and education. Despite these gains, the presence of residual IAH underscores the need for continued screening and tailored management to further mitigate hypoglycemia risks in this vulnerable population.
Funding and Clinical Trials Information
The original publication did not specify funding sources or clinical trial registration details.
References
Delaney PWJ, Hayes E, Rajan R, Smith GJ, Davis EA, Jones TW, Abraham MB. Reduced Prevalence of Impaired Awareness of Hypoglycemia Over Two Decades in Population-Based Samples of Youth With Type 1 Diabetes. Diabetes Care. 2026 Jul 1;49(7):1280-1284. PMID: 42138725.
Heller SR, Cryer PE. Impaired hypoglycemia awareness in type 1 diabetes: pathophysiology and prevention. Diabetes. 1996 Sep;45(9):1363-70. doi:10.2337/diab.45.9.1363.
Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378. doi:10.1001/jama.2016.19975.
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024 Jan;47(Suppl 1):S39-S49.